Researchers at the Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy and the Centre of Public Health, Queen’s University… Read More »Anti-VEGF treatments for diabetic macula oedema (DMO) reports Cochrane review meta-analysis.
Researchers at the UCL Institute of Ophthalmology, London, UK have reported early pre-clinical research using non-viral gene therapy treatments for certain inherited retinal degenerations (IRDs),… Read More »Non-viral vectors for gene therapy may accommodate large genes, such as USH2A for Usher syndrome patients.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 5th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »July 5th, 2023 “EURETINA-Brief”© Issue No. 274
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key data from a Phase 2b multi-centre RCT (NCT04945772) of “MCO-010” (sonpiretigene isteparvovec), an… Read More »Nanoscope Therapeutics Inc., have announced key results for Phase 2b (“RESTORE”) for the treatment of retinitis pigmentosa (RP) using optogenetic therapy.
Researchers at the Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, have reported results on the prevalence of disease-causing variants in LCA-associated genes… Read More »Clinical and genetic profile of retinopathies among LCA patients in a large German cohort.
Researchers at Radboud University Medical Center, Nijmegen, the Netherlands, have reported a novel approach to use exon skipping that may “patch” part of a gene… Read More »Therapeutic exon skipping strategies of Usher syndrome (USH2A) may provide mutation-independent approaches for treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the June 18th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »June 18th, 2023 “EURETINA-Brief”© Issue No. 273
Astellas Pharma Inc. (TSE: 4503) and IVERIC Bio, Inc. (NASDAQ: ISEE) have announced a definitive agreement on May 1st under which Astellas has agreed to… Read More »Astellas Pharma Inc., (TSE: 4503) is to acquire Iveric Bio Inc., (NASDAQ: ISEE) for a purchase of US$5.9bn.
International clinical researchers at several collaborating institutes, from Pennsylvania to Istanbul, have reported results on the genetic contribution of the HLA-B/MICA genetic region to the… Read More »Genetic analysis in Behçet’s disease identifies novel loci associated with ocular and neurological involvement.
Researchers at the Institute of Basic Medical Sciences, University of Oslo, the Norwegian Association of the Blind and Partially Sighted, Oslo, and Roche Norway (F Hoffmann-La… Read More »Analysis reports the treatment burden of intravitreal anti-VEGF injections among a Norwegian cohort of patients and caregivers on nAMD.
